See more : Nucor Corporation (0K9L.L) Income Statement Analysis – Financial Results
Complete financial analysis of Silk Road Medical, Inc (SILK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silk Road Medical, Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- New Japan Chemical Co., Ltd. (4406.T) Income Statement Analysis – Financial Results
- MEG Energy Corp. (MEG.TO) Income Statement Analysis – Financial Results
- United Company RUSAL, International Public Joint-Stock Company (0486.HK) Income Statement Analysis – Financial Results
- Oi Wah Pawnshop Credit Holdings Limited (1319.HK) Income Statement Analysis – Financial Results
- NickelX Limited (NKL.AX) Income Statement Analysis – Financial Results
Silk Road Medical, Inc (SILK)
About Silk Road Medical, Inc
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 177.13M | 138.64M | 101.48M | 75.23M | 63.35M | 34.56M | 14.26M |
| Cost of Revenue | 50.05M | 37.88M | 25.45M | 21.29M | 15.93M | 10.87M | 5.13M |
| Gross Profit | 127.09M | 100.76M | 76.03M | 53.94M | 47.43M | 23.68M | 9.13M |
| Gross Profit Ratio | 71.75% | 72.68% | 74.92% | 71.70% | 74.86% | 68.53% | 64.03% |
| Research & Development | 41.32M | 36.45M | 27.11M | 21.27M | 12.27M | 10.26M | 7.24M |
| General & Administrative | 144.57M | 115.97M | 96.17M | 75.33M | 62.86M | 34.82M | 20.26M |
| Selling & Marketing | 461.00K | 347.00K | 221.00K | 194.00K | 362.00K | 186.00K | 218.00K |
| SG&A | 145.03M | 116.32M | 96.39M | 75.52M | 63.22M | 34.82M | 20.26M |
| Other Expenses | 442.00K | -190.00K | -23.00K | -80.00K | -21.05M | -12.06M | 2.93M |
| Operating Expenses | 186.36M | 152.77M | 123.50M | 96.80M | 75.49M | 45.08M | 27.50M |
| Cost & Expenses | 236.41M | 190.64M | 148.94M | 118.09M | 91.42M | 55.95M | 32.63M |
| Interest Income | 9.96M | 2.53M | 198.00K | 1.10M | 1.66M | 189.00K | 34.00K |
| Interest Expense | 6.87M | 5.10M | 2.52M | 4.41M | 4.95M | 4.36M | 3.94M |
| Depreciation & Amortization | 3.79M | 3.17M | 1.92M | 1.39M | 1.29M | 517.00K | 128.72K |
| EBITDA | -45.08M | -46.74M | -45.55M | -41.47M | -46.17M | -32.75M | -18.25M |
| EBITDA Ratio | -31.32% | -35.82% | -46.61% | -55.51% | -41.68% | -94.78% | -107.20% |
| Operating Income | -59.27M | -52.00M | -47.47M | -42.86M | -28.07M | -21.40M | -18.37M |
| Operating Income Ratio | -33.46% | -37.51% | -46.78% | -56.97% | -44.30% | -61.91% | -128.87% |
| Total Other Income/Expenses | 3.53M | -3.01M | -2.34M | -4.51M | -24.35M | -16.24M | -982.00K |
| Income Before Tax | -55.74M | -55.01M | -49.81M | -47.37M | -52.42M | -37.63M | -19.36M |
| Income Before Tax Ratio | -31.47% | -39.68% | -49.09% | -62.96% | -82.73% | -108.89% | -135.76% |
| Income Tax Expense | 43.00K | 3.01M | 576.00K | 3.02M | 3.66M | -11.87M | 6.87M |
| Net Income | -55.74M | -58.02M | -50.39M | -50.39M | -56.07M | -37.63M | -19.36M |
| Net Income Ratio | -31.47% | -41.85% | -49.65% | -66.98% | -88.51% | -108.89% | -135.76% |
| EPS | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| EPS Diluted | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| Weighted Avg Shares Out | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
| Weighted Avg Shares Out (Dil) | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
Silk Road Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 42nd Annual J.P....
Silk Road Medical, Inc (SILK) Q3 2023 Earnings Call Transcript
Silk Road Medical, Inc (NASDAQ:SILK ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Director, Investor Relations Jack Lasersohn - Chairman Chas McKhann - Chief Executive Officer Lucas Buchanan -...
Silk Road Medical Reports Third Quarter 2023 Financial Results
SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2023.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SILK). Such investors are advised to contact Robert S.
Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Silk Road Medical to Report Third Quarter 2023 Financial Results on November 8, 2023
SUNNYVALE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2023 after...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK
NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SILK). Such investors are advised to contact Robert S.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK
NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SILK). Such investors are advised to contact Robert S.
Why Shares of Silk Road Medical Are Dropping Wednesday
Silk Road Medical is a medical device company that focuses on preventing strokes. The company released preliminary third-quarter numbers and reduced yearly revenue guidance.
Silk Road Medical stock plummets on CEO exit and revenue downgrade
Silk Road Medical (NASDAQ:SILK) stock halved in value at the start of Wednesday's trading after an after-hours profit warning. The company, which has developed a treatment for carotid artery disease, which is a cause of stroke, on Tuesday downgraded revenue guidance...
Source: https://incomestatements.info
Category: Stock Reports